Since angioedema due to ACE inhibitors is a result of inhibition of bradykinin degradation (or perhaps other peptides inactivated by ACE), and not bradykinin overproduction, the only agent used to treat HAE that is likely to be effective is Icatibant. This evidence concerns the gene ACE and hereditary angioedema.